Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TIGER-diabetes: Low vs Standard Dose Ticagrelor in ACS
NCT04307511Phase 4Recruiting
- Sponsor
- Shanghai Tongren Hospital
- Start
- Apr 2020
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of ticagrelor in acute coronary syndrome (ACS) (2 arms), sponsored by Shanghai Tongren Hospital. Primary endpoints: Platelet Reactivity Index at 2 months and Maximum Amplitude at 2 months. Started Apr 2020; status: recruiting.
02
Drugs
ticagrelor
03
Conditions
acute coronary syndrome (ACS)
Beyond the preview
Go deeper on NCT04307511.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04307511.